The PAM used in the IU - led study worked by amplifying two brain compounds — anandamide and 2 - arachidonoylglycerol — commonly called «endocannabinoids» because they act upon the CB1 receptor in the brain that responds to THC,
the major psychoactive ingredient in cannabis.